Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Prices Public Offering Of Common Shares


Tuesday, 18 Jun 2013 07:25pm EDT 

Valeant Pharmaceuticals International Inc announced that it has priced its previously announced public offering of common shares (the Offering). Pursuant to the Offering, the Company will issue 23,529,412 common shares at a price of $85.00 per share, for aggregate gross proceeds of approximately $2.0 billion. The Company will file a final prospectus supplement to its effective shelf registration statement on Form S-3 and will make a similar filing with the securities regulatory authorities in each of the provinces of Canada. Closing of the Offering is expected to occur on or about June 24, 2013. The Company intends to use the net proceeds from the Offering, together with debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt. If the Merger were not to close for any reason, the proceeds of the Offering will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions. Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada. 

Company Quote

146.061
3.381 +2.37%
12:26pm EST